<DOC>
	<DOCNO>NCT00889200</DOCNO>
	<brief_summary>This study design use sensitive neuroendocrine probe , Dexamethasone/Corticotropin-Releasing Hormone ( DEX/CRH ) test , sample healthy adult insomnia . The primary aim ass cortisol reactivity long-term ( 6 week ) administration eszopiclone . It hypothesize treatment eszopiclone would result significant reduction plasma cortisol response DEX/CRH test follow treatment insomnia standard dose eszopiclone .</brief_summary>
	<brief_title>Eszopiclone Treatment &amp; Cortisol Responsivity</brief_title>
	<detailed_description>see</detailed_description>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Mild Moderate Insomnia Any acute chronic medical condition involve function HPA axis ( e.g. , Cushing 's Addison 's Disease , adrenal pituitary gland disorder ) Currently take , unable free , antidepressant , neuroleptic , anxiolytic , thymoleptic drug least 2 week precede DEX/CRH test ( free fluoxetine least 6 week ) Current use psychotropic medication medication ( prescribed counter ) think affect HPA axis function glucocorticoid synthesis/release ( e.g. , prednisone , anabolic steroid , DHEA , ketoconazole , metyrapone ) History significant adverse reaction eszopiclone Meets DSMIV criterion Axis I psychiatric disorder , include substance abuse presently , substance dependence within past 6 month Pregnancy , lactation , unable/unwilling use reliable method contraception study procedure Limited mental competency inability give inform , voluntary , write consent participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>